(CLOX) Series Portfolios Trust - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • • Ultrashort Bond
CLOX: Collateralized, Loan, Obligations, Rated, Securities
The Series Portfolios Trust (NYSE ARCA: CLOX) is an actively managed exchange-traded fund (ETF) designed to capitalize on the stability of high-rated collateralized loan obligations (CLOs). Under normal market conditions, the fund allocates at least 80% of its net assets (plus borrowings for investment purposes) to CLOs rated AAA or equivalent by a nationally recognized statistical rating organization (NRSRO). If a CLO is unrated, the funds adviser assesses its quality to ensure equivalence. CLOs are structured financial instruments that pool together leveraged loans, offering predictable cash flows due to their seniority in the capital structure. This focus on AAA-rated CLOs aims to provide exposure to a low-risk segment of the leveraged loan market, particularly appealing in environments where credit spreads are stable or tightening. The fund is non-diversified, meaning it can concentrate its holdings in a smaller number of securities, which may increase risk but also allows for targeted exposure to the CLO market.
As an ultrashort bond ETF, CLOX is structured to deliver returns with minimal interest rate sensitivity, making it suitable for investors seeking stable income in a rising or falling rate environment. The funds active management allows the portfolio team to select CLOs with favorable terms, such as lower leverage, stronger collateral pools, and attractive spreads. Additionally, the ETFs focus on the AAA tranche of CLOs provides a layer of protection against defaults, as these securities are senior to other tranches and typically have lower loss absorption. The funds average volume of 14,774 shares over the past 20 days and assets under management (AUM) of $107.30 million indicate moderate liquidity, which is common for niche fixed-income ETFs. Its current price of $25.51 reflects its net asset value (NAV) plus a minimal premium, as evidenced by the tight spread between its last price and short-term moving averages (SMA 20: $25.57, SMA 50: $25.47).
3-Month Forecast: Based onAdditional Sources for CLOX ETF
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CLOX ETF Overview
Market Cap in USD | 107m |
Category | Ultrashort Bond |
TER | 0.21% |
IPO / Inception | 2023-07-18 |
CLOX ETF Ratings
Growth 5y | 54.5% |
Fundamental | - |
Dividend | 62.5% |
Rel. Strength Industry | 6.61 |
Analysts | - |
Fair Price Momentum | 25.73 USD |
Fair Price DCF | - |
CLOX Dividends
Dividend Yield 12m | 5.80% |
Yield on Cost 5y | 6.43% |
Annual Growth 5y | 47.18% |
Payout Consistency | 100.0% |
CLOX Growth Ratios
Growth Correlation 3m | 97.4% |
Growth Correlation 12m | 99.8% |
Growth Correlation 5y | 99.9% |
CAGR 5y | 7.39% |
CAGR/Max DD 5y | 15.08 |
Sharpe Ratio 12m | 1.76 |
Alpha | 2.36 |
Beta | 0.01 |
Volatility | 1.71% |
Current Volume | 284.8k |
Average Volume 20d | 11.2k |
As of March 14, 2025, the stock is trading at USD 25.49 with a total of 284,811 shares traded.
Over the past week, the price has changed by -0.25%, over one month by +0.24%, over three months by +1.13% and over the past year by +6.59%.
Partly, yes. Based on ValueRay Analyses, Series Portfolios Trust (NYSE ARCA:CLOX) is currently (March 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 54.48 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CLOX as of March 2025 is 25.73. This means that CLOX is currently overvalued and has a potential downside of 0.94%.
Series Portfolios Trust has no consensus analysts rating.
According to ValueRays Forecast Model, CLOX Series Portfolios Trust will be worth about 27.8 in March 2026. The stock is currently trading at 25.49. This means that the stock has a potential upside of +9.02%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 27.8 | 9% |